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Abstract
Background Drug–drug interactions (DDIs) cause significant morbidity and mortality, especially in patients with HIV with 
opportunistic infections such as tuberculosis. However, the literature on quantitative signal detection analyses for DDIs within 
the national spontaneous reporting systems (SRSs) of countries with high HIV/tuberculosis burdens is lacking.
Objective Our objective was to explore the utility of using post-marketing SRSs in quantitative signal detection analyses 
of DDIs.
Methods A case/non-case analysis using the Zimbabwean adverse drug reaction (ADR) database obtained from  VigiBase® 
was utilized for quantitative signal detection using 2 × 2 contingency table calculations. Cases were defined as individual 
case safety reports (ICSRs) with the ADR of interest, and non-cases included the rest of the ICSRs. The exposure of interest 
was the use of a drug of interest.
Results Signals of disproportionate reporting (SDRs) were observed for hepatotoxicity for the combined use of highly 
active antiretroviral therapy (HAART) and antitubercular treatments (ATT) [ADR reporting odds ratio (ROR) 43.78; 95% 
CI 5.24–366.08], HAART and isoniazid (ROR 44.84; 95% CI 5.36–374.99), and isoniazid and nevirapine-based HAART 
(ROR 35.60; 95% CI 9.39–134.89). SDRs were also observed for the combined use of nevirapine-based HAART and co-
trimoxazole for Stevens–Johnson syndrome (ROR 28.91; 95% CI 14.00–59.70), severe cutaneous ADRs (ROR 16.10; 95% 
CI 9.40–27.57), and rash (OR 2.18; 95% CI 1.69–2.81).
Conclusion It is feasible to conduct signal detection analyses for DDIs within relatively small SRS databases. However, the 
observed potential SDR for the respective DDI should be investigated further as the method is only a hypothesis-generation 
analysis.
Introduction
Drug–drug interactions (DDIs) are defined as the modifica-
tion of the safety and/or efficacy profile of any medicine 
concomitantly administered with one or more other drugs 
[1]. They result from the alteration of the pharmacological 
effects of one drug because of the actions of the co-adminis-
tered drug leading to unpredictable and/or predictable clini-
cal effects [2]. DDIs often lead to treatment inefficacy and/
or substantial morbidity [3]. They account for 30% of all 
adverse drug reactions (ADRs) [4, 5] and between 1 and 5% 
of hospital admissions in the general population and elderly 
populations, respectively [6]. DDIs can be classified as phar-
macodynamic, pharmacokinetic, or pharmaceutical interac-
tions, depending on the involved mechanism of action [7].
DDIs are difficult to detect because of their low incidence 
rates and even lower reporting rates [3, 8, 9]. However, some 
data mining algorithms have been developed for spontane-
ous reporting systems (SRSs) to confirm known signals or 
to flag and ultimately prioritize the clinical review of poten-
tial signals of DDIs [3, 8]. SRS provides a larger pool of 
patients exposed to a substantial number of co-medications, 
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unlike the situation in pre-marketing clinical trials [8]. This 
improves the detectability of rarer ADRs, such as DDIs, 
using univariate logistic regression and additive and mul-
tiplicative modelling, amongst others [8, 10, 11]. Previous 
studies have validated the utility of detecting signals of dis-
proportionate reporting (SDR) in SRSs such as  VigiBase® 
or in smaller, national databases [4, 9, 12]. As such, post-
marketing surveillance, as exemplified by SRS, can detect 
rare and long-latency ADRs, unlike randomized controlled 
trials, which have limited drug co-prescriptions and duration 
of follow-up [8]. However, SRSs have several limitations, 
including under-reporting, poor reporting of concomitant 
medications, and unavailability of denominator data.
Similar approaches may be useful in assessing potential 
DDI signals with the concurrent use of highly active antiret-
roviral therapy (HAART) and drugs for the treatment and 
prevention of opportunistic infections. It has previously been 
suggested that DDIs between non-nucleotide reverse tran-
scriptase inhibitors (NNRTIs) and rifampicin in resource-
limited settings should be assessed, given the restricted for-
mularies and use of standardized therapies and fixed-dose 
combinations alongside limited therapeutic drug monitoring 
services [13, 14]. Moreover, the commonly available NNR-
TIs, nevirapine and efavirenz, have well-documented over-
lapping toxicities with rifampicin, which may lead to poor 
adherence and treatment interruptions [15, 16]. As it is criti-
cally important to provide HAART and antitubercular treat-
ment (ATT) to patients co-infected with HIV/tuberculosis in 
resource-limited settings to reduce morbidity and mortality, 
HAART must be compatible with ATT to avoid potential or 
actual DDIs with rifampicin [17, 18]. Our group has pre-
viously reported on the higher frequency of some ADRs 
(e.g. hepatic disorders, peripheral neuropathy, and rash) 
in patients exposed to both antiretrovirals and ATT using 
spontaneous adverse reaction data [19]. In this study, we 
explored the utility of using the Zimbabwean post-marketing 
SRS for quantitative signal detection analyses of potential 
DDIs between antiretroviral drugs, ATT, and cotrimoxazole. 
We hypothesised that concurrent use of antiretrovirals and 
prophylactic medicines for tuberculosis or opportunistic dis-
eases increase the risk of certain ADRs.
Methods
Setting and design
We carried out a case/non-case analysis for some preferred 
terms (PTs) or ADRs of interest in the Zimbabwean SRS 
database for individual case safety reports (ICSRs) mention-
ing a drug exposure of interest observed during the report-
ing period [20]. All ICSRs captured within  VigiBase® from 
Zimbabwe collected from 1997 to 2018 were extracted and 
included in the analyses, as previously described by Masuka 
and Khoza [21]. The reported ADRs were coded using the 
Medical Dictionary for Regulatory Activities (MedDRA), 
version 21.0, at the PT level. All drugs were classified 
according to the anatomical therapeutic classification (ATC) 
system at level 1, and all reported medicines were consid-
ered in the analyses regardless of the causality assessment.
Selection of cases and non‑cases
Cases were defined as ICSRs with the PT/ADR of inter-
est, whereas non-cases (controls) were defined as all other 
ICSRs. The chosen HAART/ATT and HAART/cotrimoxa-
zole combinations were considered the exposures of interest, 
and the remaining drugs were not considered exposures of 
interest. Positive and negative controls were used to investi-
gate undetected biases in the study using known drug–drug 
combinations and their outcomes [20]. The known interac-
tion between isoniazid and stavudine, leading to peripheral 
neuropathy, was used as a positive control, whereas the lack 
of known DDIs between tenofovir and cotrimoxazole was 
used as a negative control [22].
Drug–drug event combinations were selected from cited 
toxicity overlaps between HAART (ATC code J05AR) and 
ATT (J04AM) [15, 16]. Additional analyses were conducted 
for particular HAART combinations, such as nevirapine-
based HAART or efavirenz-based HAART in combination 
with ATT for the same events. A similar approach was used 
for combinations of cotrimoxazole and HAART or ATT. 
These drug–drug event combinations were based on obser-
vations from our group’s previous study [19]. Furthermore, 
related PTs were combined to form new identifier event 
terms as previously done by van Puijenbroek et al. [10]. Two 
ADRs of special interest (ADRSIs) were created for analysis 
as alternatives to the PT event levels [23, 24]: severe cutane-
ous adverse drug reaction (SCAR) comprised acute general-
ized exanthematous pustulosis, drug-induced hypersensitiv-
ity syndrome (DIHS), drug reaction with eosinophilia and 
systemic symptoms (DRESS), erythema multiforme, Ste-
vens–Johnson syndrome (SJS), and toxic epidermal necroly-
sis (TEN) [25]. All selected drug–drug event combinations 
were initially reviewed against DDI information held in the 
freely available Liverpool HIV DDI interaction checker [22].
Statistical analysis
The detection of DDIs was based on the concept that when 
an ADR is reported more often for a combination of two 
drugs, D1 and D2 versus either D1 or D2 alone, then D1 and 
D2 interact when used in combination [3, 10]. ADR reporting 
odds ratios (RORs) were calculated for each drug–drug event 
using a bivariate disproportionality analysis, represented by 
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the 2 × 2 contingency table (Table 1) and formally indicated 
in Eqs. 1 and 2 [20, 26]:
where a, b, c, and d are the respective frequencies indicated 
in Table 1 and CI is confidence interval.
Drug–drug event combinations for the concurrent use of 
D1 and D2 with a lower bound of the 95% confidence interval 
(CI) for the ROR > 1 were considered SDRs [10, 20, 23]. An 
SDR was considered more likely to be due to a DDI if the 
95% CI for concomitant use was mutually exclusive of the 
two index groups [10]. Statistical analyses were conducted 
using the Statistical Package for Social Sciences (SPSS), 
version 16. The RORs and their associated 95% CIs were 
calculated using an online statistical calculator (Select Sta-
tistical Services, Exeter, UK) [27]. In addition, all analyses 
were premised on a further assumption that the SRS data 
are representative of the event rate in the population using 
the medicines [9].
Results
A total of 4072 ICSRs were used in this analysis, of which 
2560 and 540 were for HAART- and ATT-containing medi-
cations, respectively. The most commonly reported HAART 
combinations in the database were tenofovir/lamivudine/
efavirenz (785; 30.66%), followed by stavudine/lamivudine/
nevirapine (526; 20.55%), and tenofovir/lamivudine/nevirap-
ine (302; 11.80%) from 2560 HAART-containing ICSRs. 
Isoniazid and rifampicin were co-reported in 123 of the 540 
ATT-containing ICSRs, and isoniazid was solely reported in 
409 ICSRs. Cotrimoxazole was reported in 1052 ICSRs and 
co-reported with HAART in 870 ICSRs.
Signals of disproportionate reporting
Potential SDRs were observed for the PTs hepatotoxicity and 





(2)95% CI = eln (ROR)±1.96
√
(1∕a+1∕b+1∕c+1∕d),
was particularly observed for the concurrent use of HAART 
and isoniazid and of nevirapine-based HAART and isonia-
zid, as evidenced by the higher observed RORs. Concurrent 
use of HAART and rifampicin was also statically significant 
for both hepatotoxicity and jaundice, although the RORs 
were smaller, as shown in Table 2.
Potential SDRs were also observed for the ADRSI SCAR 
and the PTs SJS and rash, especially with the concurrent use 
of nevirapine-based HAART and cotrimoxazole. No simi-
lar, statistically significant interactions were observed for 
the concurrent use of efavirenz-based HAART and cotri-
moxazole, as evidenced by RORs inclusive of 1, as shown in 
Table 3. The a priori selected positive and negative controls 
were confirmed as known signals and non-signals, respec-
tively, as shown in Table 4.
Discussion
In the current study, we explored whether it was feasible 
to quantitatively detect potential DDIs using a relatively 
small SRS database. Poorly characterized DDIs involving 
antiretrovirals, ATT, and cotrimoxazole were chosen for the 
demonstration using an SRS database from a country with 
a high HIV and tuberculosis burden [28, 29]. ADRs are 7.4 
times more common in patients with concurrent HIV and 
tuberculosis, whereas DDIs occur in up to 18% of patients 
with HIV [28, 30]. Using 2 × 2 contingency tables, we dem-
onstrated that exploratory signal detection analyses are feasi-
ble within small databases, as previously discussed by Caster 
et al. [12]. Thus, timely quantitative signal detection can 
potentially be conducted using small databases from rela-
tively underdeveloped pharmacovigilance systems, which 
will improve patient safety.
Several studies have indicated significant DDIs between 
HAART and ATT or antimicrobial drugs in Africa [13, 28, 
29, 31]. In this study, we observed potential SDR for the 
hepatic system MedDRA PTs hepatotoxicity and jaundice 
associated with the concurrent use of nevirapine-based 
HAART and ATT or isoniazid prophylactic therapy (IPT). 
These observations strengthen the clinically and quali-
tatively observed signals of possible DDIs between nevi-
rapine-based HAART and IPT [19]. These findings have 
also recently been highlighted in the paediatric population 
within a Zimbabwean specialist HIV clinic setting [32]. 
Previous studies indicated minimal hepatotoxicity risk with 
the concurrent use of nevirapine-based HAART and isonia-
zid and/or ATT [33]. However, some of these studies were 
of short duration or were largely composed of participants 
not receiving HAART [33]. Isoniazid appears to cause a 
pharmacokinetic DDI with nevirapine, resulting in elevated 
serum concentrations of nevirapine [34], possibly explaining 
the current observations.
Table 1  2 × 2 contingency table for the calculation of adverse drug 
reaction reporting odds ratios
ADR adverse drug reaction
Medication ADR of interest “cases” Other ADR 
“non-cases”
Drug of interest a b
Other drugs c d
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Similarly, potential SDRs were observed for the co-
administration of nevirapine-based HAART and cotrimox-
azole for the PTs rash and SJS and the medically impor-
tant term, SCAR. In one case–control study, concurrent 
nevirapine-based HAART and ATT was associated with an 
increased risk for severe cutaneous ADRs, including SJS 
and DIHS/DRESS [35]. The authors postulated that this 
observation may be due to concomitantly administered cot-
rimoxazole, though this hypothesis was not analysed [35]. 
SCAR, particularly SJS/TEN secondary to concurrent use of 
nevirapine-based HAART and cotrimoxazole prophylactic 
therapy, has been observed in a similar Sub-Sahara Afri-
can population [36]. Concurrent use of nevirapine-based 
HAART and cotrimoxazole has been associated with hepa-
totoxicity. Furthermore, increased aminotransferase levels 
were associated with rashes [37].
The major strengths of this validated, frequentist dispro-
portionality analysis include reasonable sensitivity and easy 
applicability and interpretability [20]. Non-selective under-
reporting of a drug or an ADR does not influence the value 
of the ROR compared with the population experiencing 
the ADR [26]. Furthermore, this study used de-duplicated 
ADRs not reported as DDIs, which potentially enhances 
the study’s internal validity [19]. Stratification and/or sub-
grouping minimized selection and competition biases [20]. 
The use of “control drug–drug events” ruled out undetected 
biases since it verified known and unknown signals for posi-
tive and negative controls, respectively [9, 20].
The risk of the observed signals being spurious might be 
minimal [12]; however, there are a multitude of significant 
limitations in this study. First, the small database and the 
incomplete reporting of ADRs and/or concurrent medica-
tions limit the reliability of the SRS-derived data for quan-
titative signal detection. Second, this small database also 
limited the precision and the magnitude of the observed 
potential SDRs as indicated by the wide 95% CIs [38]. 
For instance, it is difficult to know with certainty whether 
patients were receiving IPT or ATT, as ICSRs frequently 
lack data on concomitant medications, amongst other param-
eters [20]. Thus, the observed RORs are only indicative 
Table 2  Adverse event reporting odds ratios depicting the occurrence of hepatotoxicity and jaundice
EFV efavirenz, INH isoniazid, J04AM antimycobacterial drugs, J05AR antiretroviral drug class, NVP nevirapine, RIF rifampicin, ROR reporting 
odds ratio
Exposure Hepatotoxicity Jaundice
Cases Controls ROR (95% CI) Cases Controls ROR (95% CI)
J05AR–J04AM
 Neither J05AR nor J04AM 1 1131 1 3 1129 1
 J05AR 10 2389 4.73 (0.61–37.03) 30 2369 4.77 (1.45–15.65)
 J04AM 5 374 15.12 (1.76–129.83) 15 364 15.51 (4.46–53.87)
 Concomitant J05AR + J04AM 6 155 43.78 (5.24–366.08) 24 137 65.93 (19.60–221.81)
J05AR–INH
 Neither J05AR nor INH 1 1136 1 4 1133 1
 J05AR 10 2392 4.75 (0.61–37.14) 30 2372 3.58 (1.2–10.19)
 INH 5 369 15.39 (1.79–132.18) 14 360 11.02 (3.60–33.68)
 Concomitant J05AR + INH 6 152 44.84 (5.36–374.99) 24 134 50.73 (17.34–148.43)
J05AR–RIF
 Neither J05AR nor RIF 4 1400 1 10 1434 1
 J05AR 14 2487 1.97 (0.65–6.00) 50 2451 2.93 (1.48–5.79)
 RIF 2 65 10.77 (1.94–59.87) 8 59 19.44 (7.40–51.06)
 Concomitant J05AR + RIF 2 57 12.28 (2.20–68.44) 4 55 10.43 (3.17–34.29)
EFV–INH
 Neither EFV nor INH 9 2545 1 24 2530 1
 EFV 2 983 0.58 (0.12–2.67) 10 975 1.08 (0.52–2.27)
  INH 9 241 10.56 (4.15–26.85) 32 218 15.47 (8.95–26.74)
 Concomitant EFV + INH 2 280 2.02 (0.43–9.39) 6 276 2.29 (0.93–5.65)
NVP–INH
 Neither NVP nor INH 4 2449 1 23 2430 1
 NVP 7 1079 3.97 (1.16–13.60) 11 1075 1.08 (0.53–2.23)
 INH 6 435 8.44 (2.37–30.05) 19 422 4.76 (2.57–8.81)
 Concomitant NVP + INH 5 86 35.60 (9.39–134.89) 19 72 27.88 (14.54–53.47)
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for all DDIs with concurrent isoniazid IPT or ATT. The 
observed RORs may have been overestimated because of 
selection bias, particularly indication bias, because we did 
not stratify the analyses according to therapeutic class [20].
In addition to under-reporting, competition, selection, 
and surveillance biases may limit the interpretability of 
the presented results [11, 20]. Clinical limitations such 
as poor reporting of concomitant alcohol and/or herbal 
medications and assumption of 100% drug adherence 
and standardized dosing further limit the study’s validity. 
The described approach may only be useful for synergis-
tic rather than antagonistic interactions [11]. Moreover, 
our approach limited the study because we did not test 
for interaction effects or correct for covariates as done in 
a logistic regression modelling approach [10, 20]. How-
ever, a review of the Liverpool HAART drug interaction 
checker did not indicate some of the SDRs observed in our 
study. Similarly, the University of California, San Fran-
cisco HIV InSite antiretroviral database does not indicate 
any of the observed SDRs [39].
In conclusion, quantitative signal detection analyses for 
potential, unrecognized, or poorly characterized SDR of 
DDIs is feasible within relatively small SRS databases. 
This is especially important for DDIs resulting from 
HAART and/or ATT in Sub-Sahara Africa. The region has 
a high background rate of comorbid HIV and tuberculosis 
and use of standardized therapy and fixed-dose HAART 
and/ATT drug combinations, lacks affordable alternative 
medicines, and has significantly weak drug safety monitor-
ing systems [14]. The detection of SDRs does not imply a 
causal relationship; it only generates hypotheses, possibly 
just at par with case reports and/or series [9, 10, 41]. The 
clinical validity of the raised hypotheses must be further 
reviewed and evaluated by subject matter experts [41]. 
Further assessment of the observed potential SDRs using 
larger datasets and/or controlled epidemiologic studies is 
needed to verify findings from disproportionalty analyses 
[40, 41].
Table 3  Adverse event reporting odds ratios depicting the occurrence of rash, Steven–Johnson syndrome, and SCAR 
CTX cotrimoxazole, EFV efavirenz, J05AR antiretroviral drug class, NVP nevirapine, ROR reporting odds ratio, SCAR severe cutaneous adverse 
drug reaction
Exposure Rash Steven–Johnson syndrome SCAR 
Cases Controls ROR (95% CI) Cases Controls ROR (95% CI) Cases Controls ROR (95% CI)
J05AR–CTX
 Neither J05AR nor CTX 213 1116 1 6 1323 1 16 1313 1
 J05AR 232 1458 0.83 (0.68–1.02) 47 1643 6.31 (2.69–14.80) 55 1635 2.76 (1.57–4.84)
 CTX 46 136 1.77 (1.27–2.55) 10 172 12.82 (4.60–35.71) 14 168 6.84 (3.28–14.26)
 Concomitant 
J05AR + CTX
147 723 1.07 (0.85–1.37) 46 824 12.31 (5.23–28.95) 55 815 5.54 (3.15–9.73)
EFV–CTX
 Neither EFV nor CTX 343 1842 1 48 2137 1 64 2121 1
 EFV 102 732 0.75 (0.59–0.95) 5 829 0.27 (0.11–0.68) 7 827 0.28 (0.13–0.61)
 CTX 128 491 1.40 (1.12–1.76) 49 570 3.83 (2.54–5.76) 57 562 3.36 (2.32–4.86)
 Concomitant EFV + CTX 65 368 0.95 (0.71–1.26) 7 426 0.73 (0.33–1.63) 12 421 0.94 (0.51–1.77)
NVP–CTX
 Neither NVP nor CTX 289 1979 1 9 2259 1 19 2249 1
 NVP 156 595 1.75 (1.41–2.17) 44 707 15.62 (7.59–32.16) 52 699 8.81 (5.17–14.99)
 CTX 88 538 1.09 (0.84–1.41) 12 614 4.91 (2.06–11.70) 18 608 3.5 (1.82–6.72)
 Concomitant NVP + CTX 105 321 2.18 (1.69–2.81) 44 382 28.91 (14.00–59.70) 51 375 16.1 (9.40–27.57)
Table 4  Adverse event  reporting odds ratios for positive and nega-
tive controls
CTX cotrimoxazole, D4T stavudine, INH isoniazid, ROR reporting 
odds ratio, TDF tenofovir
Exposure Cases Controls ROR (95% CI)
Anaemia TDF–CTX
 Neither TDF nor CTX 29 1927 1
 TDF 19 1044 1.21 (0.67–2.17)
 CTX 16 425 2.50 (1.35–4.65)
 Concomitant 
TDF + CTX
17 594 1.90 (1.04–3.49)
Peripheral neuropathy D4T–INH
 Neither D4T nor INH 22 2870 1
 D4T 227 420 70.51 (44.98–110.52)
 INH 25 470 6.94 (3.88–12.41)
 Concomitant use 
D4T + INH
21 16 171.22 (78.97–371.25)
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Take home messages
• Quantitative disproportionate analyses for drug–drug 
interactions are feasible in relatively small spontaneous 
adverse drug reaction reporting systems.
• Concomitant use of antiretrovirals and isoniazid poten-
tially increases the risk of hepatotoxicity.
• Concomitant use of nevirapine-based antiretrovirals 
and cotrimoxazole potentially increases the risk of 
cutaneous adverse drug reactions.
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